An interventional study of Clinic-wide Trainings and Clinic-wide Trainings and HIV Prevention Decision Support Tool (DST) in Human Immunodeficiency Virus, Human Immunodeficiency Virus Transmission and Sexually Transmitted Diseases, sponsored by University of California, San Francisco. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by University of California, San Francisco · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Sexually Transmitted Diseases by University of California, San Francisco — 1 open to participants now, 1 under way, none of them phase 3. Sexually Transmitted Diseases · University of California, San Francisco.
Among the 13 studies in Sexually Transmitted Diseases by University of California, San Francisco, this one is the 8th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2022, is one of 8 with no phase, and was the 12th registered.
525 studies on the registry are indexed under Sexually Transmitted Diseases; 79 are open to participants now.
Browse Sexually Transmitted Diseases studies →1 of the 13 studies in Sexually Transmitted Diseases by University of California, San Francisco is open now, in 1 country. Recruiting first, the newest first:
University of California, San Francisco · Sites in Kenya
Ages 15+ · Healthy volunteers
By country, each count listing its studies:
Of the 49 Sexually Transmitted Diseases studies recruiting now, 30 (61%) set no upper age limit and 17 (35%) stop at 75 or younger; 23 take children under 18; 33 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 141 is below the median of 449 across 426 interventional studies indexed under Sexually Transmitted Diseases.
Median enrollment 509 across the 10 interventional studies, 907 across the 3 observational. Of the 12 that completed or were terminated, 6 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of California, San Francisco is the lead sponsor of 2,172 studies on the registry; 370 are open to participants now.
Of its 269 completed or terminated interventional studies of FDA-regulated products, 203 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Sexually Transmitted Diseases by University of California, San Francisco, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To address the significant barriers to pre-exposure prophylaxis (PrEP) implementation for cisgender women and address racial inequities in HIV prevention in the United States (US), a novel approach that accounts for multilevel influences is necessary. This study is the second part (Aim 2) of a multi-component project and involves a patient- and clinic-level intervention in a public health reproductive health clinic and an STI clinic in Duval County Florida, where most patients are women of color. The area has one of the highest HIV incidence rates among women in the US. The investigators developed 1) a tablet-based decision support tool (DST) that helps users learn about HIV vulnerabilities and HIV prevention strategies to inform how they consider options for reducing their likelihood of acquiring HIV, and 2) clinic-wide trainings regarding shared decision making and trauma informed care. In Aim 1 (previously completed), participants were randomized to viewing an HIV prevention DST in a clinic that had not received clinic-wide trainings. In Aim 2 (the present study), there will be two phases. In the first phase, participants will receive care at the clinics following training; the DST will not be used. In the second phase, in addition to being seen at a clinic-site that has experienced the training, participants will use the DST before their visit. Participants will be surveyed about experiences with HIV prevention counseling, intentions about using HIV prevention, and DST use (among those in the active arm in the second phase). A subset of participants, individuals who self-identify as Black or Latinx, will also complete a post-clinic visit interview. The investigators will assess whether participants initiated an HIV prevention method three months following their initial visit. The main outcomes will include a quantitative and qualitative assessment of PrEP or other HIV prevention use, decisional certainty, and satisfaction with information about HIV prevention options.
Although 13% of the U.S. female population is Black, 60% of new HIV diagnoses in U.S. women occur among Black women. The South is the epicenter of the U.S. HIV epidemic, including in women, and Black Southern women are disproportionately affected: Black women account for 69% of new HIV diagnoses in women in the South. As the first highly effective, discrete, woman-controlled HIV prevention method, oral pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate/emtricitabine radically expands HIV prevention options for women. However, uptake of PrEP in U.S. women has lagged, particularly among groups most affected by HIV.
PrEP cascades outline the necessary steps for accessing PrEP, including screening and identifying eligible individuals, linkage to care, prescription, and initiation of PrEP. Data suggest there are multilevel barriers related to the process of screening for HIV risk in women and identifying potential PrEP candidates that may drive a significant drop off early in the PrEP cascade for women. Women report feeling judged by risk assessment questions and experience stigma around disclosing sexual practices. As a result, if screening is required to educate patients about PrEP - as is true in most clinical settings - many women for whom PrEP is appropriate may never learn about PrEP. Further, women have low levels of knowledge about HIV risk and HIV prevention options, and therefore will not seek out PrEP services themselves. Lastly, there is often limited time to educate patients in busy clinics. By offering education to all women about vulnerabilities to HIV as well as information about HIV prevention methods including PrEP, at-risk women can circumvent these multifactorial barriers and request PrEP. Electronic decision support tools (DST), which have been used with success in a range of healthcare contexts including contraception, provide an efficient and private mechanism for this information-sharing step.
The study team developed a tablet-based tool that is designed to provide universal PrEP education and facilitate women's agency to identify their own risks and interest in PrEP. It was refined with iterative feedback from patient and community stakeholders and finalized based on cognitive testing.
The DST provides information about vulnerabilities to HIV, and emphasizes the variable and individual nature of baseline risk. It provides information on the core characteristics of different HIV prevention methods, and then the opportunity to explore these characteristics in depth, including efficacy, safety and side effects. The user chooses the level of information that they wish to receive through the interactive interface, allowing for an individualized experience. Upon reaching the end of the tool, information on the tablet suggests that women ask their provider about HIV prevention methods they are interested in using, based on their preferences for method characteristics, and their questions to facilitate deliberation with the provider. The DST takes approximately 10 minutes to complete. A decision support tool was chosen as a key component of the study following its proven effectiveness in offering contraceptive options to patients. The HIV prevention DST was tested in Aim 1 of this study: participants were randomized to viewing the DST or not, prior to receiving usual care.
Additionally, the study team recognizes the importance of receiving health information from a trusted source, such as health care providers or health educators, when making important health decisions. Therefore, this study (Aim 2) will offer and assess the effects of a combined intervention of the DST following a clinic-wide training on shared decision making and trauma-informed care. Shared decision making is an effective strategy to offer information and services to patients as it allows the health care provider to share their clinical knowledge and expertise while partnering with the patient to elicit their experiential knowledge, needs and preferences. Through partnership between a patient and provider, the patient can make an informed decision about HIV prevention and other health needs that align with their values and desires and can result in greater adherence to the prevention or treatment options and satisfaction with care. The training will also include information about trauma-informed approaches to deliver health care in a person-centered and affirming manner. This training will highlight how many people, particularly those vulnerable to HIV due to intersecting oppressions, carry traumas that impact their exposure to health issues and the resources needed to mitigate these harms. It is critical that health care providers and health professionals are aware of intersecting forms of oppression that create trauma, including those that the medical profession create and perpetuate. A combined approach of shared decision making at the interpersonal level and trauma informed care at the clinic-level is an equity-oriented strategy to offering HIV prevention information to women in the Southeastern U.S. who are disproportionately impacted by HIV.
Approximately 366 individuals who self-identify as women presenting to a reproductive health clinic and an STI clinic in Duval County, Florida, will be recruited to the study in Aim 2, with 183 enrolled in each of the two phases. As the decision support tool is primarily focused on cisgender women, participants who do not identify as cisgender will be included in the study, but their study data will be analyzed separately. In the first phase of Aim 2 of the study, participants will receive care as usual at a clinic site after the trainings have been held for staff. In the second phase of Aim 2, participants will receive care at this same clinic that has been exposed to the training and will also view the HIV prevention DST. These participants will be compared to those recruited in Aim 1 of this study, in which participants accessed care from the same clinic prior to clinic-wide trainings, and half of participants viewed the HIV prevention DST.
In addition to these interventions, a subset of up to 80 participants (40 per phase) will be asked to allow audio-recording of their counseling sessions with a provider. A subset of up to 80 additional participants (40 per phase), all of whom self-identify as women of color, will be invited to complete one-hour, semi-structured interviews after their clinic visit about their experiences of using the DST, HIV prevention counseling, and decision making about PrEP. Those who participated in Aim 1, are not excluded from participating in Aim 2 however, they will not be eligible to participate in an interview.
Hypotheses:
525 studies on the registry are indexed under Sexually Transmitted Diseases; 79 are open to participants now.
This study's enrollment of 141 is below the median of 449 across 426 interventional studies indexed under Sexually Transmitted Diseases.
Browse Sexually Transmitted Diseases studies →University of California, San Francisco is the lead sponsor of 2,172 studies on the registry; 370 are open to participants now.
Of its 269 completed or terminated interventional studies of FDA-regulated products, 203 (75%) have results posted.
Compared within Sexually Transmitted Diseases, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Acquired Immunodeficiency Syndrome. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this arm will receive care in a clinic where providers and staff have been trained in shared decision making and trauma-informed care. Participants in this arm will not view the decision support tool in this phase.
Other: Clinic-wide Trainings
Participants in this arm will receive care in a clinic where providers and staff have been trained in shared decision making and trauma informed care, and receive the HIV prevention DST intervention immediately before their provider visit.
Other: Clinic-wide Trainings and HIV Prevention Decision Support Tool (DST)
The clinic-wide trainings combine principles of shared decision-making and trauma informed care to inform providers and clinic staff of an equitable approach to offering HIV prevention information. These care delivery approaches have been used in health education and counseling in a range of contexts and are effective strategies for care provision. Participants in this arm will receive care from providers and staff who received training.
The clinic-wide trainings combine principles of shared decision-making and trauma informed care to inform providers and clinic staff of an equitable approach to offering HIV prevention information. These care delivery approaches have been used in health education and counseling in a range of contexts and are effective strategies for care provision. Participants in this arm will receive care from providers and staff who received training. The DST is founded on principles of decision-science and will address barriers to PrEP delivery. The DST will present HIV prevention information through a tablet in the clinical setting. The tool provides information about vulnerabilities to HIV and core characteristics of different HIV prevention methods, and the opportunity to explore these characteristics in depth, including efficacy, safety and side effects. The tool emphasizes the highly variable and individual nature of baseline risk.
PrEP Prescriptions (As Measured by Chart Review)
The number of participants who received a PrEP prescription within 3 months of their index clinical visit, obtained by chart extraction from the medical record. Outcome is dichotomous (Yes, received a PrEP prescription at initial visit/No, did not receive a PrEP prescription at initial visit).
Time frame: 3 months post clinical visit
Number of Patients Reporting PrEP Use
Patients will be contacted at follow-up and asked if they took PrEP in the past 3 months regardless of where it was obtained. Outcome is dichotomous ("Yes", initiated PrEP within 3 months of index visit/"No", did not initiate PrEP within 3 months of index visit)
Time frame: 3 months post clinical visit
Change in Patient-Perceived HIV Risk
We will measure the change in HIV risk perception from pre- to post- index clinical visit. Response options include 4-point scale: 1 ("Not at all worried") to 4 ("Extremely worried"). Used to varify reports of change in worry over time. No independent estimates of effect performed.
Time frame: Immediately preceding clinical visit compared to immediately following clinical visit
Patient-Perceived HIV Risk
Participants will be asked about how worried they are about getting HIV in the next 6 months. Response options include 4-point scale of 1 ("Not at all worried") to 4 ("Extremely worried").
Time frame: Immediately post clinical visit
PrEP Knowledge
Percentage of participants selecting the correct response to three questions. Response options for each item are different. Higher score represents higher knowledge.
Time frame: Immediately post clinical visit
Decisional Conflict - Total Score
16-item scale to measure decisional conflict. Response options range from 1-5 "strongly disagree" to "strongly agree". Mean score will be calculated, subtracted by 1, and multiplied by 25; scores range from 0 \[no decisional conflict' to 100 \[extremely high decisional conflict\].Higher scores represent high decisional conflict.
Time frame: Immediately post clinical visit
Decisional Conflict - Uncertainty Subscore
Three items from the Decisional Conflict scale will measure uncertainty: "I am clear about the best choice for me", "I feel sure about what to choose", and "the decision is easy for me to make". Response options range from 1-5 "strongly disagree" to "strongly agree". Items will be reverse-coded. Mean scores will be calculated, subtracted by 1, and multiplied by 25; scores range from 0 \[feels extremely certain about best choice\] to 100 \[feels extremely uncertain about decision\]. Higher scores represent greater decision uncertainty.
Time frame: Immediately post clinical visit
Decisional Conflict - Informed Subscore
Three items from the Decisional Conflict scale will measure the informed subscale: "I know which options are available to me", "I know the benefits of each option", and "I know the risks and side effects of each option". Response options range from 1-5 "strongly disagree" to "strongly agree". Items will be reverse-coded. Mean scores will be calculated, subtracted by 1, and multiplied by 25; scores range from 0 \[feels extremely informed\] to 100 \[feels extremely uninformed\]. Higher scores represent a greater degree of feeling uninformed.
Time frame: Immediately post clinical visit
Decisional Conflict - Values Clarity Subscore
Three items from the Decisional Conflict scale will measure values clarity: "I am clear about which benefits matter the most to me", "I am clear about which risks and side effects matter most to me", and "I am clear about which is more important to me (the benefits or the risks and side effects." Response options range from 1-5 "strongly disagree" to "strongly agree". Items will be reverse-coded. Mean scores will be calculated, subtracted by 1, and multiplied by 25; scores range from 0 \[feels extremely clear about personal values for benefits and risks/side effects\] to 100 \[feels extremely unclear about personal values\].
Time frame: Immediately post clinical visit
Decisional Conflict - Support Subscore
Three items from the Decisional Conflict scale will measure support: "I have enough support from others to make a choice", "I am choosing without pressure from others", and "I have enough advice to make a choice". Response options range from 1-5 "strongly disagree" to "strongly agree". Items will be reverse-coded. Mean scores will be calculated, subtracted by 1, and multiplied by 25; scores range from 0 \[feels extremely supported in decision making\] to 100 \[feels extremely unsupported in decision making\].
Time frame: Immediately post clinical visit
Decisional Conflict - Effective Decision Subscore
Four items from the Decisional Conflict scale will measure effective decision: "I feel I have made an informed choice", "my decision shows what is important to me", "I expect to stick with my decision", and "I am satisfied with my decision". Response options range from 1-5 strongly disagree to strongly agree. Items will be reverse-coded. Mean scores will be calculated, subtracted by 1, and multiplied by 25; scores range from 0 \[good decision\] to 100 \[bad decision\].
Time frame: Immediately post clinical visit
Interpersonal Quality of HIV Prevention Care
Median score of 4-item scale. Derived from the Person-Centered Contraceptive Care measure developed by the PI. Response options consist of 5-point Likert scale: 1 ("strongly disagree") to 5 ("strongly agree"). Minimum possible score is 0 and maximum possible score is 20, with higher scores indicating better care. Scores will be dichotomized between 20 \[excellent interpersonal quality of care\] and less than 20 \[poor interpersonal quality of care\].
Time frame: Immediately post clinical visit
Interpersonal Quality of Health Services
Median score of 4-item scale. Derived from the Person-Centered Contraceptive Counseling measure developed by the PI. Response options consist of 5-point Likert scale: 1 ("strongly disagree") to 5 ("strongly agree"). Minimum possible score is 0 and maximum possible score is 20, with higher scores indicating better care. Scores will be dichotomized between 20 \[excellent interpersonal quality of care\] and less than 20 \[poor interpersonal quality of care\]. This measure will exclude HIV prevention care and focus on other services offered.
Time frame: Immediately post clinical visit
Intention to Use Any HIV Prevention Method
A one time, one item measure of plan to use HIV prevention method after the initial visit. Participants can select from "none", condoms, PrEP, PEP, treatment as prevention, regular HIV testing (inclusive of partner), "still thinking about my options", or other method.
Time frame: Immediately post clinical visit
Confidence in Decision to Use an HIV Prevention Method
A one-time, one-item measure of certainty of plan to use HIV prevention after the initial visit. Participants can select from four options: 1 ("completely unsure"), 2 ("mostly unsure"), 3 ("mostly sure, but not 100%"), or 4 ("100% sure"). Presented as the percentage who reported being "fully sure" about HIV prevention method. Reporting here the percent who reported high confidence.
Time frame: Immediately post clinical visit
Satisfaction With Information Received About HIV Prevention
Participants will be asked a one-time question regarding satisfaction with HIV prevention counseling. Response options include: 1 ("I was not given any information about HIV), 2 ("Very unsatisfied") 3 ("Somewhat unsatisfied), 4 ("Neither satisfied or unsatisfied"), 5 ("Somewhat satisfied") and 6 ("Very satisfied").
Time frame: Immediately post clinical visit
Perceived Quality of Information Received About HIV Prevention
Participants will also be asked four questions about the perceived quality of the HIV prevention information patients received during their health care visit: 1) getting the information they needed, 2) the ease of understanding the information, 3) the trustworthiness of the information, and 4), the usefulness of the information. These questions will be asked of those who reported talking about HIV/HIV prevention during their visit with the healthcare provider or health educator OR those who talked to the healthcare provider or health educator about your chances of getting HIV. Response options are 1 to 5 "strongly disagree" to "strongly agree". Higher values indicate greater perceived quality. Recorded here are percentage of participants who "strongly agreed" with each statement.
Time frame: Immediately post clinical visit
Perceived Quality of Health Information Received
Participants will also be asked four questions about the perceived quality of the health information patients received during their health care visit, excluding HIV prevention information: 1) getting the information they needed, 2) the ease of understanding the information, 3) the trustworthiness of the information, and 4), the usefulness of the information. These questions will be asked of those who reported talking about alcohol or drugs, intimate partner violence or abuse, pregnancy, contraception or birth control, STDs (not including HIV) or STD prevention, or other, during their visit with the healthcare provider or health educator. Response options are 1 to 5 "strongly disagree" to "strongly agree". Higher values indicate greater perceived quality.
Time frame: Immediately post clinical visit
Acceptability of HIV Prevention Methods
Participants are asked to rate their preference for a method (even if they never used it). Participants can select from condoms, PrEP, PEP, treatment as prevention or other method. The option, "never heard of it" is also included. Options for this scale range from 0 ("Terrible method for me") to 10 ("Great method for me"). Recorded here is percent of participants who responded "great for me" to each item
Time frame: Immediately post clinical visit
Acceptability of the Decision Support Tool
Participants who used the DST in the second phase of the study are asked four questions about their experiences using the DST (e.g., degree to which they got all the information they needed, found the information to be easy to understand, trust the information, and found information useful). Response items vary from strongly disagree to strongly agree. Reported here are the percentage of the participants who reported "strongly agree" to each item.
Time frame: Immediately post clinical visit
Perception of the Decision Support Tool
Participants who used the DST in the second phase of the study will be asked about the degree to which they liked/disliked the tool. Response options vary: "I did not like it at all", "I somewhat liked it", "I somewhat liked it", or "I really liked it".
Time frame: Immediately post clinical visit
Satisfaction With the Decision Support Tool
Participants who used the DST in the second phase of the study will be asked about the degree to which they are satisfied with the information in the tool. Response options vary from 1-5: "very unsatisfied" to "very satisfied".
Time frame: Immediately post clinical visit
Recommend the Decision Support Tool
Participants who used the DST in the second phase of the study will be asked about whether they would recommend the decision support tool to a friend. Response options are "yes", "no", and "unsure".
Time frame: Immediately post clinical visit
Willingness to Use the Decision Support Tool at Future Visits
Participants who used the DST in the second phase of the study will be asked about whether they would use the tool again if they returned to the clinic. Response options are "yes", "no", and "unsure"
Time frame: Immediately post clinical visit
HIV Prevention Method Use (Any Method - Planned or New Method)
A self-reported measure of HIV prevention method use, including those who reported discontinuing the initial HIV prevention method(s) that were reported post-clinic visit. This item will be measured by a response of "yes" to any of the following questions: since your \[baseline\] visit, have you used....for HIV prevention - abstinence, condoms, PEP, PrEP, regular HIV testing, treatment as prevention, regular sexually transmitted disease (STD) testing, or other method. The outcome will be dichotomized to those who responded affirmatively vs other responses ("no"/"unsure").
Time frame: 3 months post clinical visit
HIV Prevention Method Continuation
A self-reported measure of HIV prevention method continuation. This item will be measured by a response of "yes" to any of the following questions: are you still using - abstinence, condoms, PEP, PrEP, regular HIV testing, treatment as prevention, regular sexually transmitted disease (STD) testing, or other method. The outcome will be dichotomized to those who responded "yes" vs "no".
Time frame: 3 months post clinical visit
Individuals will be handed a flyer about the study and eligibility criteria when they present to the front desk for check in. Interested individuals are then brought back to a private clinic room for an eligibility screening. Eligible individuals will then be enrolled into the study and randomized to either the control or intervention.
| Milestone | Care Post Clinic-Wide Trainings | Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) |
|---|---|---|
| Started | 80 | 61 |
| Completed | 48 | 38 |
| Not completed | 32 | 23 |
| Withdrew: Withdrawal by subject | 3 | 0 |
| Withdrew: Lost to follow-up | 29 | 23 |
The number of participants who received a PrEP prescription within 3 months of their index clinical visit, obtained by chart extraction from the medical record. Outcome is dichotomous (Yes, received a PrEP prescription at initial visit/No, did not receive a PrEP prescription at initial visit).
| Participants | Care Post Clinic-Wide Trainings | Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) |
|---|---|---|
| PrEP Prescriptions (As Measured by Chart Review) | 0 | 0 |
Patients will be contacted at follow-up and asked if they took PrEP in the past 3 months regardless of where it was obtained. Outcome is dichotomous ("Yes", initiated PrEP within 3 months of index visit/"No", did not initiate PrEP within 3 months of index visit)
| Participants | Care Post Clinic-Wide Trainings | Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) |
|---|---|---|
| Number of Patients Reporting PrEP Use | 1 | 3 |
We will measure the change in HIV risk perception from pre- to post- index clinical visit. Response options include 4-point scale: 1 ("Not at all worried") to 4 ("Extremely worried"). Used to varify reports of change in worry over time. No independent estimates of effect performed.
| Participants | Care Post Clinic-Wide Trainings | Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) |
|---|---|---|
| No change | 68 | 53 |
| Increased worry | 1 | 0 |
| Decreased worry | 8 | 5 |
Participants will be asked about how worried they are about getting HIV in the next 6 months. Response options include 4-point scale of 1 ("Not at all worried") to 4 ("Extremely worried").
| Participants | Care Post Clinic-Wide Trainings | Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) |
|---|---|---|
| Not at all worried | 59 | 47 |
| A little worried | 14 | 6 |
| Very worried | 3 | 2 |
| Extremely worried | 2 | 3 |
Percentage of participants selecting the correct response to three questions. Response options for each item are different. Higher score represents higher knowledge.
| Participants | Care Post Clinic-Wide Trainings | Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) |
|---|---|---|
| PrEP is a daily pill to prevent HIV | 32 | 29 |
| PrEP is for all adults | 53 | 50 |
| PrEP will not work if taken once a week | 34 | 32 |
| PrEP does not prevent STDs other than HIV | 34 | 32 |
| PrEP side effects do not last forever | 20 | 31 |
| A baby could be born to HIV discordant parents without transmitting HIV | 29 | 27 |
| There is medication that you can take after sex to prevent HIV (PEP) | 25 | 39 |
| PrEP efficacy is > 95% | 45 | 30 |
16-item scale to measure decisional conflict. Response options range from 1-5 "strongly disagree" to "strongly agree". Mean score will be calculated, subtracted by 1, and multiplied by 25; scores range from 0 \[no decisional conflict' to 100 \[extremely high decisional conflict\].Higher scores represent high decisional conflict.
| units on a scale | Care Post Clinic-Wide Trainings | Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) |
|---|---|---|
| Decisional Conflict - Total Score | 25 (0 to 27) | 2 (0 to 25) |
Three items from the Decisional Conflict scale will measure uncertainty: "I am clear about the best choice for me", "I feel sure about what to choose", and "the decision is easy for me to make". Response options range from 1-5 "strongly disagree" to "strongly agree". Items will be reverse-coded. Mean scores will be calculated, subtracted by 1, and multiplied by 25; scores range from 0 \[feels extremely certain about best choice\] to 100 \[feels extremely uncertain about decision\]. Higher scores represent greater decision uncertainty.
| units on a scale | Care Post Clinic-Wide Trainings | Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) |
|---|---|---|
| Decisional Conflict - Uncertainty Subscore | 25 (0 to 25) | 0 (0 to 25) |
Three items from the Decisional Conflict scale will measure the informed subscale: "I know which options are available to me", "I know the benefits of each option", and "I know the risks and side effects of each option". Response options range from 1-5 "strongly disagree" to "strongly agree". Items will be reverse-coded. Mean scores will be calculated, subtracted by 1, and multiplied by 25; scores range from 0 \[feels extremely informed\] to 100 \[feels extremely uninformed\]. Higher scores represent a greater degree of feeling uninformed.
| units on a scale | Care Post Clinic-Wide Trainings | Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) |
|---|---|---|
| Decisional Conflict - Informed Subscore | 25 (0 to 25) | 0 (0 to 25) |
Three items from the Decisional Conflict scale will measure values clarity: "I am clear about which benefits matter the most to me", "I am clear about which risks and side effects matter most to me", and "I am clear about which is more important to me (the benefits or the risks and side effects." Response options range from 1-5 "strongly disagree" to "strongly agree". Items will be reverse-coded. Mean scores will be calculated, subtracted by 1, and multiplied by 25; scores range from 0 \[feels extremely clear about personal values for benefits and risks/side effects\] to 100 \[feels extremely unclear about personal values\].
| units on a scale | Care Post Clinic-Wide Trainings | Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) |
|---|---|---|
| Decisional Conflict - Values Clarity Subscore | 25 (0 to 33) | 0 (0 to 25) |
Three items from the Decisional Conflict scale will measure support: "I have enough support from others to make a choice", "I am choosing without pressure from others", and "I have enough advice to make a choice". Response options range from 1-5 "strongly disagree" to "strongly agree". Items will be reverse-coded. Mean scores will be calculated, subtracted by 1, and multiplied by 25; scores range from 0 \[feels extremely supported in decision making\] to 100 \[feels extremely unsupported in decision making\].
| units on a scale | Care Post Clinic-Wide Trainings | Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) |
|---|---|---|
| Decisional Conflict - Support Subscore | 25 (0 to 25) | 0 (0 to 25) |
Four items from the Decisional Conflict scale will measure effective decision: "I feel I have made an informed choice", "my decision shows what is important to me", "I expect to stick with my decision", and "I am satisfied with my decision". Response options range from 1-5 strongly disagree to strongly agree. Items will be reverse-coded. Mean scores will be calculated, subtracted by 1, and multiplied by 25; scores range from 0 \[good decision\] to 100 \[bad decision\].
| units on a scale | Care Post Clinic-Wide Trainings | Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) |
|---|---|---|
| Decisional Conflict - Effective Decision Subscore | 19 (0 to 25) | 0 (0 to 25) |
Median score of 4-item scale. Derived from the Person-Centered Contraceptive Care measure developed by the PI. Response options consist of 5-point Likert scale: 1 ("strongly disagree") to 5 ("strongly agree"). Minimum possible score is 0 and maximum possible score is 20, with higher scores indicating better care. Scores will be dichotomized between 20 \[excellent interpersonal quality of care\] and less than 20 \[poor interpersonal quality of care\].
| units on a scale | Care Post Clinic-Wide Trainings | Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) |
|---|---|---|
| Interpersonal Quality of HIV Prevention Care | 20 (15 to 20) | 20 (16 to 20) |
Median score of 4-item scale. Derived from the Person-Centered Contraceptive Counseling measure developed by the PI. Response options consist of 5-point Likert scale: 1 ("strongly disagree") to 5 ("strongly agree"). Minimum possible score is 0 and maximum possible score is 20, with higher scores indicating better care. Scores will be dichotomized between 20 \[excellent interpersonal quality of care\] and less than 20 \[poor interpersonal quality of care\]. This measure will exclude HIV prevention care and focus on other services offered.
| units on a scale | Care Post Clinic-Wide Trainings | Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) |
|---|---|---|
| Interpersonal Quality of Health Services | 20 (16 to 20) | 20 (16 to 20) |
A one time, one item measure of plan to use HIV prevention method after the initial visit. Participants can select from "none", condoms, PrEP, PEP, treatment as prevention, regular HIV testing (inclusive of partner), "still thinking about my options", or other method.
| Participants | Care Post Clinic-Wide Trainings | Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) |
|---|---|---|
| Intention to Use Any HIV Prevention Method | 73 | 57 |
A one-time, one-item measure of certainty of plan to use HIV prevention after the initial visit. Participants can select from four options: 1 ("completely unsure"), 2 ("mostly unsure"), 3 ("mostly sure, but not 100%"), or 4 ("100% sure"). Presented as the percentage who reported being "fully sure" about HIV prevention method. Reporting here the percent who reported high confidence.
| Participants | Care Post Clinic-Wide Trainings | Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) |
|---|---|---|
| PrEP | 9 | 10 |
| Abstinence | 31 | 27 |
| Condoms | 49 | 45 |
| PEP | 9 | 12 |
| Regular HIV testing | 53 | 49 |
| Regular STD testing | 58 | 49 |
| Treatment as prevention | 21 | 21 |
Participants will be asked a one-time question regarding satisfaction with HIV prevention counseling. Response options include: 1 ("I was not given any information about HIV), 2 ("Very unsatisfied") 3 ("Somewhat unsatisfied), 4 ("Neither satisfied or unsatisfied"), 5 ("Somewhat satisfied") and 6 ("Very satisfied").
| Participants | Care Post Clinic-Wide Trainings | Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) |
|---|---|---|
| I was not given any information | 10 | 1 |
| Very unsatisfied | 1 | 3 |
| Neither satisfied or unsatisfied | 3 | 2 |
| Somewhat satisfied | 6 | 2 |
| Very satisfied | 58 | 50 |
Participants will also be asked four questions about the perceived quality of the HIV prevention information patients received during their health care visit: 1) getting the information they needed, 2) the ease of understanding the information, 3) the trustworthiness of the information, and 4), the usefulness of the information. These questions will be asked of those who reported talking about HIV/HIV prevention during their visit with the healthcare provider or health educator OR those who talked to the healthcare provider or health educator about your chances of getting HIV. Response options are 1 to 5 "strongly disagree" to "strongly agree". Higher values indicate greater perceived quality. Recorded here are percentage of participants who "strongly agreed" with each statement.
| Participants | Care Post Clinic-Wide Trainings | Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) |
|---|---|---|
| I got all the information I needed | 27 | 32 |
| Information was easy to understand | 28 | 32 |
| Trusted the information given | 31 | 33 |
| Found the information useful | 29 | 31 |
Participants will also be asked four questions about the perceived quality of the health information patients received during their health care visit, excluding HIV prevention information: 1) getting the information they needed, 2) the ease of understanding the information, 3) the trustworthiness of the information, and 4), the usefulness of the information. These questions will be asked of those who reported talking about alcohol or drugs, intimate partner violence or abuse, pregnancy, contraception or birth control, STDs (not including HIV) or STD prevention, or other, during their visit with the healthcare provider or health educator. Response options are 1 to 5 "strongly disagree" to "strongly agree". Higher values indicate greater perceived quality.
| Participants | Care Post Clinic-Wide Trainings | Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) |
|---|---|---|
| Got the information I needed | 43 | 31 |
| The information was easy to understand | 43 | 30 |
| I trusted the information | 42 | 31 |
| The information felt useful to me | 43 | 31 |
Participants are asked to rate their preference for a method (even if they never used it). Participants can select from condoms, PrEP, PEP, treatment as prevention or other method. The option, "never heard of it" is also included. Options for this scale range from 0 ("Terrible method for me") to 10 ("Great method for me"). Recorded here is percent of participants who responded "great for me" to each item
| Participants | Care Post Clinic-Wide Trainings | Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) |
|---|---|---|
| Abstinence | 30 | 20 |
| Condoms | 28 | 23 |
| PEP | 15 | 16 |
| PrEP | 15 | 14 |
| HIV testing | 38 | 32 |
| STD testing | 40 | 30 |
| Treatment as prevention | 24 | 20 |
Participants who used the DST in the second phase of the study are asked four questions about their experiences using the DST (e.g., degree to which they got all the information they needed, found the information to be easy to understand, trust the information, and found information useful). Response items vary from strongly disagree to strongly agree. Reported here are the percentage of the participants who reported "strongly agree" to each item.
| Participants | Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) |
|---|---|
| I got all of the information I need from the DST | 34 |
| Information on the DST was easy to understand | 37 |
| I trusted the information on the DST | 37 |
| The information felt helpful to me | 33 |
Participants who used the DST in the second phase of the study will be asked about the degree to which they liked/disliked the tool. Response options vary: "I did not like it at all", "I somewhat liked it", "I somewhat liked it", or "I really liked it".
| Participants | Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) |
|---|---|
| I did not like it all | 1 |
| I somewhat liked it | 6 |
| I really liked it | 52 |
Participants who used the DST in the second phase of the study will be asked about the degree to which they are satisfied with the information in the tool. Response options vary from 1-5: "very unsatisfied" to "very satisfied".
| Participants | Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) |
|---|---|
| Very unsatisfied | 1 |
| Somewhat satisfied | 6 |
| Very satisfied | 52 |
Participants who used the DST in the second phase of the study will be asked about whether they would recommend the decision support tool to a friend. Response options are "yes", "no", and "unsure".
| Participants | Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) |
|---|---|
| Would recommend DST | 58 |
| Would not recommend DST | 1 |
Participants who used the DST in the second phase of the study will be asked about whether they would use the tool again if they returned to the clinic. Response options are "yes", "no", and "unsure"
| Participants | Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) |
|---|---|
| Yes | 47 |
| No | 8 |
| Unsure | 4 |
A self-reported measure of HIV prevention method use, including those who reported discontinuing the initial HIV prevention method(s) that were reported post-clinic visit. This item will be measured by a response of "yes" to any of the following questions: since your \[baseline\] visit, have you used....for HIV prevention - abstinence, condoms, PEP, PrEP, regular HIV testing, treatment as prevention, regular sexually transmitted disease (STD) testing, or other method. The outcome will be dichotomized to those who responded affirmatively vs other responses ("no"/"unsure").
| Participants | Care Post Clinic-Wide Trainings | Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) |
|---|---|---|
| HIV Prevention Method Use (Any Method - Planned or New Method) | 39 | 35 |
A self-reported measure of HIV prevention method continuation. This item will be measured by a response of "yes" to any of the following questions: are you still using - abstinence, condoms, PEP, PrEP, regular HIV testing, treatment as prevention, regular sexually transmitted disease (STD) testing, or other method. The outcome will be dichotomized to those who responded "yes" vs "no".
| Participants | Care Post Clinic-Wide Trainings | Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) |
|---|---|---|
| HIV Prevention Method Continuation | 37 | 33 |
Collected over from enrollment until end of follow-up, up to 12 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Care Post Clinic-Wide Trainings | 0/80 (0%) | 0/80 (0%) | 0/80 (0%) |
| Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) | 0/61 (0%) | 0/61 (0%) | 0/61 (0%) |
| Age, Customized(Participants) | Care Post Clinic-Wide Trainings | Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) | Total |
|---|---|---|---|
| 18-24 years old | 22 | 20 | 42 |
| 25-29 years old | 14 | 12 | 26 |
| 30-34 years old | 18 | 10 | 28 |
| 35-44 years old | 23 | 16 | 39 |
| Not reported | 3 | 3 | 6 |
| Sex: Female, Male(Participants) | Care Post Clinic-Wide Trainings | Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) | Total |
|---|---|---|---|
| Female | 80 | 61 | 141 |
| Male | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Care Post Clinic-Wide Trainings | Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 2 | 2 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 57 | 46 | 103 |
| White | 11 | 7 | 18 |
| More than one race | 6 | 4 | 10 |
| Unknown or Not Reported | 3 | 1 | 4 |
| Ethnicity (NIH/OMB)(Participants) | Care Post Clinic-Wide Trainings | Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) | Total |
|---|---|---|---|
| Hispanic or Latino | 14 | 4 | 18 |
| Not Hispanic or Latino | 64 | 54 | 118 |
| Unknown or Not Reported | 2 | 3 | 5 |
| Parental Education(Participants) | Care Post Clinic-Wide Trainings | Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) | Total |
|---|---|---|---|
| 8th grade or less | 3 | 5 | 8 |
| Some high school | 10 | 15 | 25 |
| High school graduate | 39 | 22 | 61 |
| Some college | 17 | 9 | 26 |
| 4-yer college graduate | 5 | 4 | 9 |
| More than 4 year college completed | 4 | 3 | 7 |
| Not reported | 2 | 3 | 5 |
| Yearly income(Participants) | Care Post Clinic-Wide Trainings | Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) | Total |
|---|---|---|---|
| Less than $10,000 | 22 | 24 | 46 |
| $10,000-$19,999 | 22 | 8 | 30 |
| $20,000-$29,999 | 13 | 8 | 21 |
| $30,000-$39,999 | 11 | 10 | 21 |
| $40,000-$49,999 | 4 | 3 | 7 |
| $50,000-$74,999 | 5 | 4 | 9 |
| $75,000-$99,999 | 1 | 1 | 2 |
| Not reported | 2 | 3 | 5 |
| Educational attainment(Participants) | Care Post Clinic-Wide Trainings | Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) | Total |
|---|---|---|---|
| 8th grade or less | 3 | 1 | 4 |
| Still in high school | 2 | 3 | 5 |
| Less than a high school diploma | 6 | 2 | 8 |
| High school graduate | 34 | 33 | 67 |
| Some college | 26 | 15 | 41 |
| 4-year college graduate | 4 | 1 | 5 |
| More than 4-year college | 3 | 3 | 6 |
| Not reported | 2 | 3 | 5 |
| Housing status(Participants) | Care Post Clinic-Wide Trainings | Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) | Total |
|---|---|---|---|
| Rent or own | 51 | 41 | 92 |
| Living in a shelter | 0 | 0 | 0 |
| Living in a treatment facility | 0 | 1 | 1 |
| Staying with friends | 26 | 16 | 42 |
| Staying in a hotel | 1 | 0 | 1 |
| Missing | 2 | 3 | 5 |
18 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2022 to primary completion in Oct 2024, 22 months.
Results were first posted in Nov 2026, 2 years after primary completion. A results delay was requested in Sep 2025.
Of 173 non-industry interventional studies with no phase under Sexually Transmitted Diseases, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 47. This study's 22 months is below that.
Counting every sponsor, half of 183 studies reached it within 31 months; a quarter within 16 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sexually Transmitted Diseases →
University of California, San Francisco →